
A longitudinal saliva study found changes in three epigenetic-aging measures, with results differing by clock and age group.

A report dated 2026-11-10 described a longitudinal study led by Alicia Schowe at the Max Planck Institute of Psychiatry. The researchers compared saliva DNA samples collected before Germany's first containment measures in March 2020 with samples collected between September 2021 and May 2022.
In the study's overall analyses, three of four epigenetic measures showed statistically significant increases: PedBE, GrimAge2 and DunedinPACE. Horvath did not show a significant change. The study's contribution to longevity research is a record of changing aging-related markers across the pandemic period, with the pattern depending on the measure and the participant's age group. As the published study summary indicates, the findings concern epigenetic measurements rather than demonstrated changes in healthspan or lifespan.
This study was conducted in humans using repeated saliva DNA-methylation samples. It was not an animal or in vitro study.
According to the study report, the researchers analyzed samples from 1,028 participants in Germany. The group included 359 children and 385 adolescents alongside 284 adults. This age breakdown matters because the researchers examined both overall changes and patterns within each age group.
Each participant contributed a pre-pandemic sample and a later sample. That makes the design different from a comparison of unrelated people measured at different times. The central observation was change within the same participants across the interval between assessments.
ScienceAlert's account reported that the authors described the pandemic as a “natural experiment” occurring between repeated assessments. That phrase captures the study's unusual timing: researchers already had baseline samples before major societal changes occurred. The design gave them an opportunity to examine how the measured markers differed at a later assessment.
The researchers assessed DNA methylation using Horvath, PedBE, GrimAge2 and DunedinPACE. The first three estimate epigenetic age or its deviation from chronological age. DunedinPACE instead estimates the pace of aging. These distinctions are part of the study's interpretation because the measures do not all express the same quantity.
PedBE was used only for children and adolescents. It therefore did not contribute an adult result. When reading the overall finding that three measures increased, it is important to keep that age-specific application attached to the finding.
The published summary reported an overall estimate of b = 0.17 for PedBE. It reported b = 0.08 for GrimAge2 and b = 0.13 for DunedinPACE. Each had P < 0.0001. These are study-model estimates, not percentages of participants who aged faster or years added to anyone's life.
A useful reading approach is to keep the name of each measure beside its result. Replacing all the measurements with a single phrase such as “biological age increased” removes distinctions the researchers retained. The overall result is more informative when presented as a pattern across named measures.
The study report described significant increases on one measure among children and three of four measures among adolescents. Adults showed increases on two measures. Adolescents therefore had the broadest pattern of significant changes across the measures assessed in their age group.
The study summary also reported an association between perceived pandemic burden and a larger increase in aging pace among adolescents. That association was not reported for children or adults. The finding is specific to an age group and to perceived burden rather than a uniform relationship across the entire sample.
The same summary reported associations between pre-pandemic risk factors and changes in epigenetic-aging measures. Those factors included physical health and parental socioeconomic status. By contrast, the abstract summary said objective pandemic stressors were not significantly associated with those changes.
These findings deserve to remain separate when the study is discussed. The overall changes concern differences between sampling occasions. The burden finding concerns an association within adolescents. The pre-pandemic factors concern characteristics that were already present before the later assessment.
For a reader comparing coverage, that separation provides a useful check on the headline. A report about changes across the pandemic period and a report about perceived burden among adolescents describe related findings, but they are not interchangeable accounts of the same analysis.
The study report identifies several reasons to keep the conclusions narrower than a claim that the pandemic made everyone age faster:
The practical response is to ask more precise questions about biological-age claims. Which clock produced the result? What sample type was used? Which age group was assessed? Those questions keep attention on the evidence rather than on a single score presented without context.
The same reading approach applies to uncertainty in epigenetic-age estimates and to biological-age measurements in dietary intervention research. Start with the measurement and the comparison being made. Personal health concerns belong in a discussion with a qualified clinician rather than an interpretation of this population-level result alone.
The next logical step is repeated follow-up using age- and tissue-appropriate measures, alongside health outcomes and stronger comparison designs, to determine whether these epigenetic changes persist and carry meaningful implications for later health.
Assessing future claims about these pandemic-period markers requires checking how new evidence connects measurements to interventions, a step AgeAmaze supports through readable longevity reporting. Overstated claims about biological age or supplements can obscure that distinction, so the publication helps research-minded adults understand evidence strength without converting preliminary findings into promises.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.



Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog